Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis (Toddler)
Latest Information Update: 31 May 2024
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms Toddler
- Sponsors Novartis Pharmaceuticals
- 31 May 2024 New trial record